Novartis starts a new plant in Mumbai to make generic cancer drugs. It said that to reinforce our commitment to improving and extending people’s lives, Sandoz Technical Operations, a Novartis division, inaugurated its manufacturing plant for medicines and therapies at Kalwe in Mumbai today.
The plant, which marks a new chapter for Sandoz, will further strengthen the company’s operations in India to support growing healthcare needs globally.
Spread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently has a workforce of 70 people with plans to increase further to support the expansion of production capacity and capabilities.
“Today marks an important milestone for us at Novartis, and particularly for our Sandoz division, a global leader in generic pharmaceuticals and biosimilars. The inauguration of the new production and launch site for Oncology oral solids at Kalwe in India is a step forward in our constant endeavour to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs," said Sanjay Murdeshwar, country president, Novartis India.
Company said, "The new facility will manufacture oral cancer medicines for the global market and will play a key role towards enabling the delivery of high-quality cancer treatment."
Subscribe to PharmaTutor News Alerts by Email
